Obermatt
See Similar Stocks →

Kymera Therapeutics

NMQ:KYMR · US5015751044
BiotechnologySmall

360

30
Profit price67
Cash yield1
Price/Sales38
Price/Book41
Return on Capital48
Cash Return on Capital58
Return on Equity56
Profit margins20
Accruals7
Owner Earnings Margin21
Sales growth78
Profit growth10
Reinvestment71
Price momentum52
Debt load52
Refinancing71
Debt Payback1
Liquidity19
Analyst ratings48
Opinion Changes74
Price Target Upside55
Market mood76
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kymera Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2015
Employees252
Websitekymeratx.com
ISINUS5015751044
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DermatologyPulmonologyRheumatologyRespiratoryGastroenterologyInflammationChronic DiseasesOncologyImmunology

Description

Kymera Therapeutics, Inc. operates as a biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaning…

Analysis

Middle-of-the-road

Kymera Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
79
2026

All-time high

79

Jun 2026

All-time low

61

Mar 2026

Average rank

70

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
38
—
—
—
Price/Earnings
88
—
—
—
Price/Book
41
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
79
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kymera Therapeutics with its peers
Shattuck Labs
NSQ:STTK
50
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zentalis Pharmaceuticals
NMQ:ZNTL
12
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Monte Rosa Therapeutics
NSQ:GLUE
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MediciNova
NMQ:MNOV
21
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Gain Therapeutics
NMQ:GANX
59
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →